ES75
TEAS SECTION 71 & 15 RECEIVED
05/18/2026
Back to search
Official data from USPTO
THERAVANCE BIOPHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
THERAVANCE BIOPHARMA
ST13
US500000079260681Class
5, 42
Filing
79260681
Registration
6061018
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
27
Latest update
05/19/2026
Classification
Registered
Trademark type
Word
Nice classes
5, 42
Filing date
02/08/2019
Registration date
05/26/2020
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/26/2020
Last transaction
05/19/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
IE
Examiner
NEVILLE, BRIAN
Law office
M50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Theravance Biopharma Ireland Limited
Representatives
Beth H. Alter Seward & Kissel LLP
Technical classification
Nice Classes
Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticalsmedical and veterinary preparations for the treatment of human diseases of the respiratoryendocrinecirculatorygastrointestinalneurologicaloculardermatologicalgenito-urinaryintegumentaryimmune and central nervous systems; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use; diagnostic preparations and materials for medicalpharmaceutical and veterinary purposes; dietary supplements and dietetic preparations; disinfectants and antiseptics; medical dressingscoverings; pharmaceuticals and natural remedies for the treatment of human diseases of the respiratoryendocrinecirculatorygastrointestinalneurologicaloculardermatologicalgenito-urinaryintegumentaryimmune and central nervous systems; pharmaceutical products for treatment of human diseases of the respiratoryendocrinecirculatorygastrointestinalgenito-urinaryintegumentaryimmune and central nervous system; pharmaceutical preparations for the treatment of cancer and pain; pharmaceutical preparations and substances for the treatment of respiratory diseases and disorders; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations and substances for the treatment of ocular and dermatological diseases and disorders; pharmaceutical preparations and substances for the treatment of bacterial and viral infectionsnamely anti-infectives
Class 42
Scientific and technological services and research and design relating theretoscientific researchanalysisdesign and testing in the field of pharmaceuticals and medicine; medical and pharmacological research services; natural science servicesscientific researchanalysisdesign and testing in the field of natural medicine and natural remedies; testingauthentication and quality control in the field of pharmaceuticals and medicine; scientific investigation for medical purposes; bacteriologicalchemical and biological investigation in the field of pharmaceuticals and medicine
Publications
History of USPTO decisions and trademark events.
27 publications found
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
05/26/2025
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
07/23/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/17/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/24/2020
FIMP
FINAL DISPOSITION PROCESSED
09/24/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/26/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
05/26/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/10/2020
PUBO
PUBLISHED FOR OPPOSITION
03/10/2020
GPNX
NOTIFICATION PROCESSED BY IB
03/07/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/19/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/19/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/19/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/05/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/06/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/06/2020
RFNT
REFUSAL PROCESSED BY IB
08/02/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/13/2019
RFRR
REFUSAL PROCESSED BY MPU
07/13/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/26/2019
CNRT
NON-FINAL ACTION WRITTEN
06/25/2019
MAFR
APPLICATION FILING RECEIPT MAILED
06/22/2019
DOCK
ASSIGNED TO EXAMINER
06/18/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/18/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/13/2019
Continuous trademark protection
Get notified about every new filing that threatens THERAVANCE BIOPHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.